AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00561470
Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours
Trial: NCT03256292
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy
Trial: NCT00725101
Drug: Treatment for Fibromyalgia
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FM participants starting any new pharmacologic FM agent.
Trial: NCT03485911
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral capsules administered once daily
Trial: NCT01819857
Drug: Xomolix 0.625 mg intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration of 0.625 mg droperidol
Trial: NCT03597035
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study participants will receive concomitant treatment with Veltassa 8.4 grams per day and Spironolactone 25 mg per day or maximum tolerated dose. If dictated by the potassium level, Veltassa can be increased to 16.8 grams per day.
Trial: NCT02558543
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002615
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01581320
Drug: Test group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a month, administration of DP-R206 \& placebo for 16 weeks
Trial: NCT01581320
Drug: Reference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a month, administration of Bonviva \& placebo for 16 weeks
Trial: NCT00398437
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00825656
Drug: Sinol or Sinol-M nasal spray
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One spray in each nostril up to a maximum of 12 times / day on an as needed basis
Trial: NCT00100841
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00100841
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02920177
Drug: Kenalog 10 MG/ML Injectable Suspension
RxNorm normalized name: Kenalog 10 MG/ML Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL corticosteroid injection
Trial: NCT00003340
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00105287
Drug: OraVescent fentanyl (OVF)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00145301
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02134353
Drug: Placebo Comparator: Arm B - Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Arm B - Control BD for 26 weeks
Trial: NCT02204202
Drug: [18F]FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 millicuries (mCi) of \[18F\]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
Trial: NCT04347005
Drug: Cohort 1: AR882
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of AR882 or matching placebo
Trial: NCT04347005
Drug: Cohort 2: AR882
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of AR882 or matching placebo
Trial: NCT04347005
Drug: Cohort 3: AR882
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of AR882 or matching placebo
Trial: NCT04347005
Drug: Cohort 4: AR882
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of AR882 or matching placebo
Trial: NCT04347005
Drug: Cohort 5: AR882
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of AR882 or matching placebo
Trial: NCT04347005
Drug: Cohort 6: AR882 Food Effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of AR882 or matching placebo in a fed state
Trial: NCT04347005
Drug: Cohort 7: AR882 Solid Oral Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of AR882 or matching placebo
Trial: NCT01381549
Drug: GSK2251052
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
Trial: NCT00574210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablets administered twice per day
Trial: NCT04510493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours
Trial: NCT00824057
Drug: AZD6280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00256321
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/m2 PO BID from Days 1 through 14.
Trial: NCT00256321
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 400mg PO BID from Days 1 through 21.
Trial: NCT00824057
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04221321
Drug: RAPA114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAPA114 tablet
Trial: NCT00996164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will be randomized to flibanserin or placebo in a double-blind manner
Trial: NCT01482091
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
Trial: NCT01482091
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
Trial: NCT01101659
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT01101659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT00221286
Drug: pegIFN / TDF / FTC combination therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03723343
Drug: GP+IMRT
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 intravenously, d1\&d8 +Cisplatin 80 mg/m2 intravenously, d1 21\~28 days/cycle, 4 patients with oligometastasis, 6 cycles with multiple metastases
Trial: NCT03723343
Drug: TPF+IMRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel: 75mg/m2 intravenous drip, d1+Cisplatin75mg/m2 intravenous drip, d1\~d5+5-fluorouracil 750mg/m2/d intravenous drip, d1\~d521\~28 days/cycle, patients with oligometastasis take 4 cycles, moreTransfer patients for 6 cycles
Trial: NCT00028600
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep
Trial: NCT00028600
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg/sq m/d IV infusion D 1,3,\& 6: allo transpl
Trial: NCT02410083
Drug: Clopirin 1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02410083
Drug: Clopirin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01729767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are randomly placed in placebo group, besides sticking with low salt diet will take the placebo (inert ingredient) for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
Trial: NCT04378023
Drug: Neoadjuvant Chemo-radiotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
Trial: NCT02628392
Drug: DS-8500a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8500a tablets 25mg, 50mg, 75mg
Trial: NCT02628392
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching DS-8500a tablets and sitagliptin capsules
Trial: NCT02206022
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pain's evaluation for Remifentanil Group
Trial: NCT02206022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVC pain's evaluation after local anesthesia + placebo infusion
Trial: NCT04184349
Drug: LA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the LA group, only the local anesthetic infiltration will be performed by injecting the numbing medicine ropivacaine into the surgical site.
Trial: NCT04184349
Drug: B Group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the B Group,pectoral (PECS) and transversus thoracic plane(TTP) blocks will be performed by injecting the numbing medicine ropivacaine near the nerves.
Trial: NCT00322127
Drug: AMD3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.
Trial: NCT02908074
Drug: BGS649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules will be taken weekly for a maximum of 24 weeks
Trial: NCT02978391
Drug: epinephrine endoscopic injection (conventional therapy)
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: endoscopic submucosal injection of epinephrine (1: 10,000)
Trial: NCT03880981
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 600mg Po q 6 hours prn pain
Trial: NCT03880981
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 600mg po q6 hours prn pain
Trial: NCT02948309
Drug: Mistletoe extract (Iscador Qu)
RxNorm normalized name: MISTLETOE EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
Trial: NCT02948309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml subcutaneous injection 3 times/week
Trial: NCT02889666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
Trial: NCT02663297
Drug: ATLCAR.CD30 cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three dose levels will be evaluated:~Group One, 2x10\^7 cells/m\^2 (maximum dose 5x10\^7 cells)~Group Two, 1x10\^8 cells/m\^2 (maximum dose 2.5x10\^8 cells)~Group Three, 2x10\^8 cells/m\^2 (maximum dose 5x10\^8 cells)
Trial: NCT00493233
Drug: 2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)
RxNorm normalized name: ANTIPSYCHOTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period.
Trial: NCT00493233
Drug: main antipsychotic medication and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician.
Trial: NCT04734548
Drug: ApTOLL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
Trial: NCT01764997
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dispensed according to local practice.
Trial: NCT01764997
Drug: Placebo (for sarilumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01265901
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One single low-dose i.v. infusion prior to the first vaccination
Trial: NCT02201056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-935 placebo-matching oral solution
Trial: NCT03424629
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15).
Trial: NCT04221165
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids will be prescribed as per institutional standards.
Trial: NCT01039909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Trial: NCT04015518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of placebo matching Spesolimab from week 0 to 16.
Trial: NCT01085136
Drug: Investigator´s choice of chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
Trial: NCT01085136
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
Trial: NCT00953303
Drug: glucocorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
Trial: NCT00953303
Drug: standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
Trial: NCT01039909
Drug: SRT2104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
Trial: NCT03718390
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
Trial: NCT03718390
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
Trial: NCT03718390
Drug: Formulation D
RxNorm normalized name: Complete Formulation D3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
Trial: NCT04986241
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic use of statin prescribed previously by the assistant physician.
Trial: NCT00503451
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03525028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators use placebo in the control group.
Trial: NCT02759185
Drug: THC/CBD cannabis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three weeks of smoking cannabis containing equal amounts of THC and CBD with smoking limited to no more than 1.8 g per day.
Trial: NCT01199926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
Trial: NCT03163576
Drug: Phosphate Binder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT00004062
Drug: liothyronine sodium
RxNorm normalized name: Liothyronine Sodium
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02134002
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
Trial: NCT02134002
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
Trial: NCT04355806
Drug: PD-1/PD-L1 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.
Trial: NCT02428374
Drug: Rosuvastatin plus clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
Trial: NCT02428374
Drug: Rosuvastatin plus ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
Trial: NCT02428374
Drug: Simvastatin plus clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
Trial: NCT02428374
Drug: Simvastatin plus ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
Trial: NCT03919500
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants in control group are administered normal saline with the same volume and period as EPO.
Trial: NCT01573767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation powder during treatment period
Trial: NCT00775814
Drug: Candesartan and Hydrochlorothiazide
RxNorm normalized name: Candesartan and hydrochlorothiazide only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
Trial: NCT01009021
Drug: potassium diclofenac
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment